Mr. Hannah has more than 13 years of operational, finance, corporate development and company formation experience. He is responsible for leading Novosteo’s operational and finance activities, including business development, commercial strategy, investor relations, financial planning and analysis. Prior to joining Novosteo, Mr. Hannah was Chief Business Officer at Neuroptika, leading business operations and global R&D for a nerve regenerative therapeutic from preclinical studies through Phase 2.  

Previously, Mr. Hannah was Head of Corporate Development at Agenovir, a CRISPR/Cas company focused on eliminating viral reservoirs, where he led the acquisition of Agenovir by Vir Bio for up to $290M.  Prior to Agenovir, Mr. Hannah was Director of Business Development at Cidara Therapeutics (CDTX).  Mr. Hannah started his career in business development at Trius Therapeutics (TSRX) where he had increasing roles of responsibility, culminating in his group leading a $700M+ acquisition by Cubist Pharmaceuticals. During his tenure at Trius Therapeutics, Mr. Hannah led all financial modeling, strategic analytics, forecasting and valuation efforts.

Mr. Hannah received his MBA with honors from UCLA Anderson School of Management and received his BA in Economics from Colorado College.

‍